Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024

Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024

DelveInsight’s, “Chronic Pseudomonas Aeruginosa Pulmonary Infections - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Chronic Pseudomonas Aeruginosa Pulmonary Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Pseudomonas Aeruginosa Pulmonary Infections: Understanding

Chronic Pseudomonas Aeruginosa Pulmonary Infections: Overview

Pseudomonas aeruginosa (PA) is a ubiquitous Gram-negative bacterium commonly encountered in the environment and readily cleared by host defenses. However, PA is also a formidable opportunistic pathogen that can cause invasive and fulminant infections, such as acute pneumonia or bloodstream infections, in immune compromised hosts. Remarkably, the same pathogen also causes chronic infections that persist for months to decades, such as the chronic lung infection in individuals with the genetic disease cystic fibrosis (CF). Chronic PA infections thus result from a dynamic and complex interplay between pathogen and host, where bacteria persist without causing overwhelming host injury, and where host defenses fail to eradicate the pathogen.

PA has a large genome (>6 Mb) that encodes many regulatory genes involved in sensing environmental signals, controlling expression of virulence factors, metabolism and resistance mechanisms. PA thus readily adapts to a wide range of environments and can exploit this versatility to enhance its long-term survival and persistence in the host. Importantly, host-pathogen interactions evolve over time and anatomical space, with the balance fluctuating between host recognition and vigorous activation of defense mechanisms, and immune evasion and tolerance by the host.

Chronic inflammation also plays a pivotal role in its development. Administration of lipopolysaccharide (LPS) to the lungs induced severe inflammation and resulted in airspace enlargement. COPD-like changes, such as goblet cell metaplasia in the larger airways, thickening of the airway walls, and irreversible alveolar enlargement, were attained by repeated administration of LPS. Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine induced by stimuli such as LPS. Scientists reported that TNF-alpha overexpression mice in the lungs demonstrated pulmonary emphysema-like changes. MMP activation induces alveolar enlargement. Chronic inflammation caused by TNF-alpha overexpression is considered to play an important role in the development of COPD. Several reports have found that the overexpression of inflammatory cytokines, such as IL-13 and IFN-gamma, results in pathologic changes mimicking human COPD. These reports also supported the hypothesis that chronic inflammation in the lungs leads to lung tissue destruction, a hallmark of pulmonary emphysema, and chronic bronchitis.

Therefore, the role of chronic inflammation in the pathogenesis of COPD. P. aeruginosa induces chronic inflammation. The chronic inflammation, specifically that induced by P. aeruginosa, contributed to the pathogenesis of COPD.

""Chronic Pseudomonas Aeruginosa Pulmonary Infections- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pseudomonas Aeruginosa Pulmonary Infections pipeline landscape is provided which includes the disease overview and Chronic Pseudomonas Aeruginosa Pulmonary Infections treatment guidelines. The assessment part of the report embraces, in depth Chronic Pseudomonas Aeruginosa Pulmonary Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pseudomonas Aeruginosa Pulmonary Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pseudomonas Aeruginosa Pulmonary Infections R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pseudomonas Aeruginosa Pulmonary Infections.

Chronic Pseudomonas Aeruginosa Pulmonary Infections Emerging Drugs Chapters

This segment of the Chronic Pseudomonas Aeruginosa Pulmonary Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Pseudomonas Aeruginosa Pulmonary Infections Emerging Drugs

• AP-PA02: Armata Pharmaceuticals

AP-PA02 is a therapeutic phage cocktail that targets the pathogen P. aeruginosa to treat serious respiratory infections, with an emphasis on patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB). AP-PA02 is comprised of a cocktail of natural P. aeruginosa phages originating from distinct families and subfamilies, targeting multiple receptor classes, functioning with compatibility and cooperatively, and further characterized by being highly potent and having a broad host range. AP-PA02 is developed as a sterile liquid formulation, suitable for delivery by inhalation. The clinical trial material of AP-PA02 is manufactured under cGMP at Armata’s production facility in Marina Del Rey, California. Currently, the drug is being evaluated in the Phase II stage of its development of Bronchiectasis and Pseudomonal infections.

• BX004: BiomX

BiomX is developing BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections. In preclinical in vitro studies, BX004 was shown to be active against antibiotic resistant strains of P. aeruginosa and demonstrated the ability to penetrate biofilm, an assemblage of surface-associated microbial cells enclosed in an extracellular polymeric substance and one of the leading causes for antibiotic resistance. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection.

Further product details are provided in the report……..

Chronic Pseudomonas Aeruginosa Pulmonary Infections: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pseudomonas Aeruginosa Pulmonary Infections drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Pseudomonas Aeruginosa Pulmonary Infections
• There are approx. 10+ key companies which are developing the therapies for Chronic Pseudomonas Aeruginosa Pulmonary Infections. The companies which have their Chronic Pseudomonas Aeruginosa Pulmonary Infections drug candidates in the most advanced stage, i.e. Phase II include, Armata Pharmaceuticals.
• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Pseudomonas Aeruginosa Pulmonary Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Pseudomonas Aeruginosa Pulmonary Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Pseudomonas Aeruginosa Pulmonary Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pseudomonas Aeruginosa Pulmonary Infections drugs.

Chronic Pseudomonas Aeruginosa Pulmonary Infections Report Insights

• Chronic Pseudomonas Aeruginosa Pulmonary Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Pseudomonas Aeruginosa Pulmonary Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Pseudomonas Aeruginosa Pulmonary Infections drugs?
• How many Chronic Pseudomonas Aeruginosa Pulmonary Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Pseudomonas Aeruginosa Pulmonary Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Pseudomonas Aeruginosa Pulmonary Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Armata Pharmaceuticals, Inc.
• Aridis Pharmaceuticals
• Gilead Sciences
• Respirion Pharmaceuticals
• BiomX

Key Products

• AP-PA02
• AR-501
• Aztreonam
• RSP-1502
• BX004